Idea principal
Among 287 men aged 85 to 89, probable sarcopenia (reduced muscle strength alone, EWGSOP2) was seen in 73% and linked to higher mortality over 3 years (HR 3.26, 95% CI 1.38-7.70). It is a small, all-male Swedish cohort, so results may not apply to women or younger people.
Study design
Estudio de cohorte
Reading basis
Published abstract
Reading focus
Association & confounding
Esta explicación editorial está disponible en inglés, chino simplificado y chino tradicional. Esta interfaz muestra la lectura en inglés.
Pregunta de investigación
Sarcopenia, the loss of muscle function and mass, is defined differently by the European Working Group on Sarcopenia in Older People (EWGSOP) and the FNIH Sarcopenia Project, and it is unclear which definition best flags risk in very old adults. The authors compared how common sarcopenia is under each definition and how it relates to death and hospitalisation.
Población y método
Cohort study of 287 men aged 85 to 89 in the Uppsala Longitudinal Study of Adult Men (ULSAM). They had Dual X-ray Absorptiometry (DXA) for muscle mass, hand grip strength, gait speed, and a five-times chair stand test. Sarcopenia and probable sarcopenia were defined by EWGSOP (2010), EWGSOP2 (2018), and FNIH (2014). All-cause mortality and hospitalisations were registered over 3 years.
Resultados
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1Sarcopenia was seen in 21% (EWGSOP), 20% (EWGSOP2), and 8% (FNIH) of the men; probable sarcopenia (reduced muscle strength only, EWGSOP2) was seen in 73%.
- 2Sarcopenia by EWGSOP was associated with higher mortality (HR 1.95, 95% CI 1.12-3.40), and probable sarcopenia by EWGSOP2 with even higher mortality (HR 3.26, 95% CI 1.38-7.70).
- 3Probable sarcopenia (EWGSOP2) was associated with more days of hospitalisation (RR 2.12, 95% CI 1.36-3.30), and FNIH sarcopenia with more hospitalisations (RR 1.75, 95% CI 1.10-2.81).
- 4When low muscle mass was added to low strength, the definitions were associated more weakly with the outcomes, supporting the emphasis on muscle strength.
Límites e incertidumbre
- 1Only 287 men took part, so estimates are imprecise, as the wide confidence intervals show.
- 2All participants were men from one Swedish region and survived to age 85 to 89, so results may not hold for women or other populations.
- 3The abstract does not say whether results were adjusted for other health problems, so frailty or illness may explain part of the link.
- 4Follow-up was 3 years, and this reading is based on the abstract only.
Relevancia práctica
In this age group, being weak seemed more telling than having low muscle mass on a scan, which fits the focus on grip and chair-rise tests. This does not show that raising strength will lower mortality. If you or a relative notice declining strength or falls, a clinician can assess it.
Tus datos
Wearables do not measure sarcopenia, but you can follow functional tests at home: grip strength with a dynamometer or timed five-times chair stands, repeated under the same conditions. Walking speed from a tracker is a rough proxy, so look at the trend over months.
Cómo interpretar la evidencia
Exposure precedes follow-up outcomes, but confounding and reverse causation can remain. A hazard ratio is not an individual absolute risk or a demonstrated intervention effect.
Resumen estructurado de los autores English
El resumen original en inglés se reproduce con atribución bajo la licencia indicada. Es una fuente, no una interpretación de MoveVitals. El análisis preparado figura arriba; verifica los resultados importantes en la fuente.
Background
Operational definitions of sarcopenia, i.e. loss of muscle function and mass, have been proposed by the European Working Group on Sarcopenia in Older People (EWGSOP) and the Foundation for the National Institutes of Health Sarcopenia Project (FNIH). The aim of this study was to analyse the prevalence and outcome, i.e. all-cause mortality and hospitalisation, of sarcopenia and its diagnostic components in octogenarian community-dwelling men.
Methods
In total 287 men, aged 85-89 y, participating in the Uppsala Longitudinal Study of Adult Men (ULSAM) underwent Dual X-ray Absorptiometry (DXA), measurement of hand grip strength (HGS), gait speed (GS), and a five-times chair stand test (CS). Sarcopenia and probable sarcopenia were defined according to EWGSOP (2010), EWGSOP2 (2018), and FNIH (2014). All-cause mortality and hospitalisations over 3 years were registered.
Results
Sarcopenia according to EWGSOP, EWGSOP2 and FNIH was observed in 21%, 20%, and 8% of the men, respectively, while probable sarcopenia (EWGSOP2; eq. reduced muscle strength only) was seen in 73%. "Sarcopenia (EWGSOP)" and "probable sarcopenia (EWGSOP2)" were associated with increased mortality (HR 1.95, 95% CI 1.12-3.40 and HR 3.26, 95% CI 1.38-7.70, respectively). "Probable sarcopenia (EWGSOP2)" was associated with days of hospitalisation (RR 2.12, 95% CI 1.36-3.30), whereas sarcopenia according to FNIH showed an association with the number of hospitalisations (RR 1.75, 95% CI 1.10-2.81).
Conclusions
In very old men, reduced muscle strength, i.e. probable sarcopenia, was common and associated with mortality and length of stay during hospitalisation. When combined with low muscle mass (according to DXA), i.e. sarcopenia, the various definitions were associated more weakly with the adverse outcomes. The findings support the emphasis on reduced muscle strength as the major determinant of sarcopenia.
Fuentes y atribución
Sarcopenia prevalence and associations with mortality and hospitalisation by various sarcopenia definitions in 85-89 year old community-dwelling men: a report from the ULSAM study.
Sobestiansky S, Michaelsson K, Cederholm T.
BMC geriatrics · 2019-11-20
DOI: 10.1186/s12877-019-1338-1 ↗PubMed · 31747923 ↗Europe PMC · Licencia registrada: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
Interpretación editorial de MoveVitals · contenido educativo · sin revisión clínica individual registrada
Fuentes verificadas 2026-11-01
Guías prácticas
Leer en contexto
ACSM review of 137 reviews: resistance training works, and few programme details matter
The American College of Sports Medicine pooled 137 systematic reviews (over 30,000 healthy adults) and concluded that resistance training beats no exercise for strength, muscle size, power, endurance and several function tests. Few programme details changed results consistently: heavier loads (80% or more of one-repetition maximum) and 2 to 3 sets favoured strength, and at least 10 sets a week favoured muscle size, while training to failure, exercise type and periodization did not. It summarises reviews rather than new trials, gives no pooled effect sizes, and drew mostly on untrained adults and overlapping source trials.
Medicine & Science in Sports & Exercise
Nearly every resistance training plan beat no exercise; heavy loads led for strength
In a network meta-analysis of randomised trials in healthy adults (178 studies and 5097 people for strength, 119 studies and 3364 people for muscle size), nearly all resistance training prescriptions beat no exercise. Higher-load, multiset, thrice-weekly training ranked best for strength (standardised mean difference 1.60, 95% credible interval 1.38 to 1.82) and higher-load, multiset, twice-weekly training for muscle size (0.66, 0.47 to 0.85). Most prescriptions could not be statistically separated from each other (the 95% interval contained zero in 91% of the comparisons between them) and risk of bias was moderate to high, so the rankings are tentative.
British Journal of Sports Medicine
Muscle-strengthening linked to lower risk of death, heart disease, cancer and diabetes
Pooling 16 prospective cohort studies of adults, people who did muscle-strengthening activity had a 15% lower risk of all-cause mortality (RR 0.85, 95% CI 0.79 to 0.93) and a 17% lower risk of both cardiovascular disease and diabetes (RR 0.83 for each) than people who did none. The pooled mortality curve was lowest at about 40 min/week (RR 0.83), but whether larger amounts help or hurt is unclear. All of this is observational, from mostly US self-reported data, and the authors rated the certainty of evidence as very low for most outcomes.
British Journal of Sports Medicine
Protein supplements and weight training: small extra gains, smaller in older adults
Pooling 49 randomised trials with 1,863 healthy adults who did resistance training for at least 6 weeks, protein supplements added 0.30 kg of fat-free mass (95% CI 0.09 to 0.52) and 2.49 kg of one-repetition-maximum strength (0.64 to 4.33) on top of training alone. These gains were small next to the effect of training itself, were weaker with older age, and the suggested plateau near 1.6 g/kg/day was not statistically significant (p=0.079). One author has received funding from the US National Dairy Council, which supported trials in the analysis.
British Journal of Sports Medicine

